BACKGROUND: The length of postoperative drug therapy remains controversial in pulmonary tuberculosis. We analyzed our experiences to determine the postoperative duration of chemotherapy after resection. METHODS: A retrospective review was performed in 66 of 95 patients that underwent pulmonary resection for pulmonary tuberculosis between January 1993 and December 1998. We compared the relapse rates according to the length of postoperative chemotherapy in each group, classified by the results of sputum AFB culture before the surgery, the number of resistant durgs, the number of prior treatment and the division of anti-TB drugs used postoperatively. RESULTS: Fifty three of 66(80.3%) were men and 13(19.7%) were women with a median age of 33.5 years(range, 16 to 63). The mean lengths of the pre-and post-operative chemotherapies were 4.9 months, and 12.9 months respectively. Five of 66 patients(7.6%) relapsed during the mean period of follow up(39.7 months). In the group less than three times of the prior treatment, there were two relapses(20%) in Ed-the highlight above-rephrase 10 patients that were medicated for 6 months or less, and one relapse in 43 patients(2.3%) that took medicine for more than 6 months(p=0.03). In the group using second-line drugs postoperatively, there was one relapse(25%) in four patients that were medicated for 12 months or less. No patient in a total of 17 that received medicine for more than 12 months relapsed(p=0.03). CONCLUSION: We recommend that patients with the prior treatment less than three times should be treated for more than 6 months after resection and patients using the second-line drugs postoperatively should be medicated for more than 12 months.
Drug Therapy ; Female ; Humans ; Male ; Recurrence ; Retrospective Studies ; Sputum ; Tuberculosis, Pulmonary*

The type-specific PCR and the sequence analysis of 56 kDa gene of Orientia tsutsugamushi infected in field rodents specimens have shown intratypic genetic heterogeneity in genotype Karp. In sequence comparison, this genetic heterogeneity was mainly due to insertion or deletion of a repeated unit in variable domain I (VDI) region. These results suggested that genetic duplication or deletion of the specific sequence rnight be involved in intratypic genetic heterogeneity of Orientia tsutsugamushi.
Genetic Heterogeneity* ; Genotype* ; Orientia tsutsugamushi* ; Polymerase Chain Reaction ; Rodentia ; Sequence Analysis

No abstract available.
Humans ; Liver Function Tests* ; Liver*

No abstract available.
Humans ; Infant, Newborn*

No abstract available.
Herpesvirus 3, Human* ; Korea*

Early gastric cancer is defined carcinoma that is limited to the gastric mucosa and submucosa and that does not extend into the muscularis propria. The development and widespread use of upper gnstrointestinal endoscopy with biopsy and cytology have enhanced our ability to make early diagnosis of gastrie carcinoma. Gastric cancinoma is being diagnosed at an ealry stage aad the survival rates for these patients are significantly greater than those with advanced gastric carcinoma. These ealry lesion can be cured in over 90% of the cases. In fact, it is almost impossible to follow up cases of early gastric cancer without surgical treatment. We report a case developed advanced gastric carcinoma 34 months after initial endoseopic diagnosis of early gastric cancer. A, 48-year-old woman was diagnosed early gaatrie cancer on June 21, 1985 by endoscopy. Proper surgical intetvention was not carried out due to her liver cirrhosis. The follow-up endoscopic examination was done on March 16, 1988. The gastric cancer looked like an advanced stomach and extended to other site.
Biopsy ; Diagnosis* ; Early Diagnosis ; Endoscopy ; Female ; Follow-Up Studies ; Gastric Mucosa ; Humans ; Liver Cirrhosis ; Middle Aged ; Stomach ; Stomach Neoplasms* ; Survival Rate

No abstract available.
Stomach Neoplasms*

No abstract available.
Paragonimiasis*

PURPOSE: There has been little research regarding the effectiveness of oseltamivir for influenza B infections. We sought to identify the different clinical manifestations between patients treated with and without oseltamivir. METHODS: We retrospectively studied the medical records of 72 inpatients or outpatients from two medical centers diagnosed with influenza B infections by either a rapid antigen test or multiplex reverse transcriptase PCR between January 2012 and July 2012. We compared gender, age, past medical history, admission period, total fever duration, fever duration after hospitalization, post-oseltamivir medication peak temperature, laboratory test, chest X-ray, antibiotic medication, and the presence of concomitant viral or bacterial infections. RESULTS: The number of subjects in our study was 72 who were diagnosed with influenza B pneumonia, acute bronchitis, acute bronchiolitis, croup, and mean age was 3.6+/-2.8 year old. The demographic characteristics and clinical manifestations of oseltamivir and the non-oseltamivir groups, including hospitalization period (4.18+/-2.10 vs 4.79+/-1.49 days, P=.17) and total fever duration (5.32+/-2.07 vs 6.41+/-3.25 days, P=.09), demonstrated no significant differences. Notably, the oseltamivir group did have significantly reduced usage of antibiotic treatment than the non-oseltamivir group (P=.04). When we limited our patient group to patients under the age of three, similar results were seen. The group prescribed oseltamivir within 48 hours of fever onset had less antibiotic usage, in addition to a shorter fever duration. CONCLUSION: Oseltamivir appeared to have no benefit in improving the clinical course. However, if it is prescribed within the first 48 hours of symptoms, it may be more effective.
Bacterial Infections ; Bronchiolitis ; Bronchitis ; Child* ; Croup ; Fever ; Hospitalization ; Hospitals, University* ; Humans ; Influenza B virus* ; Influenza, Human ; Inpatients ; Medical Records ; Oseltamivir* ; Outpatients ; Pneumonia ; Retrospective Studies ; Reverse Transcriptase Polymerase Chain Reaction ; Thorax

No abstract available.
Animals ; Cell Line* ; Guinea Pigs* ; Guinea* ; Hantaan virus* ; Humans*